Omnix Medical
11 known investors
Find your way into Omnix Medical
Sign up to see every warm intro you have to Omnix Medical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Omnix Medical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Omnix Medical is a biopharmaceutical company founded in 2015 that develops novel antibiotic agents to treat infections caused by drug-resistant bacteria. Its lead compound, OMN6, is a first-in-class antimicrobial in Phase II clinical trials targeting drug-resistant Acinetobacter baumannii infections.
Founders & leadership

Investors · 11
How we know: the company's own site · Tal Ventures's portfolio page · calcalistech.com · the VCSheet dataset · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: Entrée Capital's portfolio page · calcalistech.com · the VCSheet dataset · Not right? Tell us
How we know: calcalistech.com · Not right? Tell us
How we know: funding news · Not right? Tell us
Also in the syndicate · 6
Funding
SEC filings, press & company announcements$25M disclosed across 1 round · 2025
- $25MSeries COct 2025 · 3 sources
EIC Fund (lead), European Innovation Council (EIC) Fund (lead), Harel Insurance & Finance (lead), Entrée Capital, Oriella Limited, OurCrowd, Prevail Partners, Tal Ventures, Xenia Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through Omnix Medical went on to found or lead other companies.
In the news
Frequently asked questions
- What does Omnix Medical do?
- Omnix Medical is a biopharmaceutical company founded in 2015 that develops novel antibiotic agents to treat infections caused by drug-resistant bacteria. Its lead compound, OMN6, is a first-in-class antimicrobial in Phase II clinical trials targeting drug-resistant Acinetobacter baumannii infections.
- Who are Omnix Medical's investors?
- Omnix Medical's investors include Tal Ventures, Xenia Venture Capital, Entrée Capital, OurCrowd, VLX Ventures.
- How much funding has Omnix Medical raised?
- Omnix Medical has disclosed $25M raised across 1 round.




